Increase in locomotor activity after acute administration of the nicotinic receptor agonist 3-bromocytisine in rats

European Journal of Pharmacology

Volumn 634, Issue 1-3, 2010, Pages 89-94

  Abin Carriquiry, Juan Andrés ^a   Urbanavicius, Jessika ^a   Scorza, Cecilia ^a   Rebolledo Fuentes, Marcos ^b   Wonnacott, Susan ^c   Cassels, Bruce K ^b   Dajas, Federico ^a  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b UNIVERSITY OF CHILE   (Chile)

^c University of Bath   (United Kingdom)

Author keywords

3 Bromocytisine; Dopamine; Locomotion; Nicotinic receptor

Indexed keywords

3 BROMOCYTISINE; 5 BROMOCYTISINE; CHLORISONDAMINE; CYTISINE; HALOPERIDOL; MECAMYLAMINE; NICOTINE; NICOTINIC AGENT; UNCLASSIFIED DRUG; 3-BROMOCYTISINE; ALKALOID; BRIDGED COMPOUND; NICOTINIC RECEPTOR; QUINOLIZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALKALOIDS; ANIMALS; BRIDGED COMPOUNDS; CHLORISONDAMINE; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAVENTRICULAR; MALE; MOTOR ACTIVITY; NICOTINIC AGONISTS; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 77951196397     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.030     Document Type: Article

References (41)

1. Abin-Carriquiry J.A., Voutilainen M.H., Barik J., Cassels B.K., Iturriaga-Vasquez P., Bermudez I., Durand C., Dajas F., Wonnacott S. C3-halogenation of cytisine generates potent and efficacious nicotinic receptor agonists. Eur. J. Pharmacol. 2006, 536:1-11.
2. Abin-Carriquiry J.A., Costa G., Urbanavicius J., Cassels B.K., Rebolledo-Fuentes M., Wonnacott S., Dajas F. In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: implications for Parkinson's Disease. Eur. J. Pharmacol. 2008, 589:80-84.
3. Bardo M.T., Bowling S.L., Pierce R.C. Changes in locomotion and dopamine neurotransmission following amphetamine, haloperidol, and exposure to novel environmental stimuli. Psychopharmacology (Berl.) 1990, 101:338-343.
4. Bednar I., Friberg L., Nordberg A. Modulation of dopamine release by the nicotinic agonist epibatidine in the frontal cortex and the nucleus accumbens of naive and chronic nicotine treated rats. Neurochem. Int. 2004, 45:1049-1055.
5. Belluzzi J.D., Lee A.G., Oliff H.S., Leslie F.M. Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats. Psychopharmacology (Berl.) 2004, 174:389-395.
6. Benwell M.E., Balfour D.J. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br. J. Pharmacol. 1992, 105:849-856.
7. Cassels B.K., Bermudez I., Dajas F., Abin-Carriquiry J.A., Wonnacott S. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. Drug Discov. Today 2005, 10:1657-1665.
8. Clarke P.B., Kumar R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br. J. Pharmacol. 1983, 78:329-337.
9. Clarke P.B., Chaudieu I., el-Bizri H., Boksa P., Quik M., Esplin B.A., Capek R. The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion. Br. J. Pharmacol. 1994, 111:397-405.
10. el-Bizri H., Clarke P.B. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine administered in vivo. Br. J. Pharmacol. 1994, 111:414-418.
11. el-Bizri H., Clarke P.B. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro. Br. J. Pharmacol. 1994, 111:406-413.
12. Exley R., Cragg S.J. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. Br. J. Pharmacol. 2008, 153(Suppl 1):S283-S297.
13. Exley R., Clements M.A., Hartung H., McIntosh J.M., Cragg S.J. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 2008, 33:2158-2166.
14. Fink J.S., Smith G.P. Mesolimbic and mesocortical dopaminergic neurons are necessary for normal exploratory behavior in rats. Neurosci. Lett. 1980, 17:61-65.
15. Fink J.S., Smith G.P. Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats. Brain Res. 1980, 199:359-384.
16. Geyer M.A., Russo P.V., Masten V.L. Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol. Biochem. Behav. 1986, 25:277-288.
17. Goshima Y., Miyamae T., Nakamura S., Miki K., Kosaka K., Misu Y. Ventral tegmental injection of nicotine induces locomotor activity and L-DOPA release from nucleus accumbens. Eur. J. Pharmacol. 1996, 309:229-233.
18. Govind A.P., Vezina P., Green W.N. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem. Pharmacol. 2009, 78:756-765.
19. Houlihan L.M., Slater Y., Guerra D.L., Peng J.H., Kuo Y.P., Lukas R.J., Cassels B.K., Bermudez I. Activity of cytisine and its brominated isosteres on recombinant human alpha7, alpha4beta2 and alpha4beta4 nicotinic acetylcholine receptors. J. Neurochem. 2001, 78:1029-1043.
20. Janhunen S., Ahtee L. Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. Eur. J. Pharmacol. 2004, 494:167-177.
21. Janhunen S., Tuominen R.K., Piepponen T.P., Ahtee L. Nicotine and epibatidine alter differently nomifensine-elevated dopamine output in the rat dorsal and ventral striatum. Eur. J. Pharmacol. 2005, 511:143-150.
22. Jimenez-Ruiz C., Berlin I., Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs 2009, 69:1319-1338.
23. King S.L., Caldarone B.J., Picciotto M.R. Beta2-subunit-containing nicotinic acetylcholine receptors are critical for dopamine-dependent locomotor activation following repeated nicotine administration. Neuropharmacology 2004, 47(Suppl 1):132-139.
24. Livingstone P.D., Wonnacott S. Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem. Pharmacol. 2009, 78:744-755.
25. Marubio L.M., Gardier A.M., Durier S., David D., Klink R., Arroyo-Jimenez M.M., McIntosh J.M., Rossi F., Champtiaux N., Zoli M., Changeux J.P. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur. J. Neurosci. 2003, 17:1329-1337.
26. Maskos U. The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology. Br. J. Pharmacol. 2008, 153(Suppl 1):S438-S445.
27. Menzaghi F., Whelan K.T., Risbrough V.B., Rao T.S., Lloyd G.K. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J. Pharmacol. Exp. Ther. 1997, 280:384-392.
28. Pawlak C.R., Schwarting R.K. Object preference and nicotine consumption in rats with high vs. low rearing activity in a novel open field. Pharmacol. Biochem. Behav. 2002, 73:679-687.
29. Pawlak C.R., Schwarting R.K. Repeated nicotine treatment in rats with high versus low rearing activity: analyses of behavioural sensitisation and place preference. Psychopharmacology (Berl.) 2005, 178:440-450.
30. Paxinos G.A.C.W. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press.
31. Prus A.J., Vann R.E., Rosecrans J.A., James J.R., Pehrson A.L., O'Connell M.M., Philibin S.D., Robinson S.E. Acute nicotine reduces and repeated nicotine increases spontaneous activity in male and female Lewis rats. Pharmacol. Biochem. Behav. 2008, 91:150-154.
32. Quik M., Campos C., Parameswaran N., Langston J.W., McIntosh J.M., Yeluashvili M. Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage. J. Mol. Neurosci. 2010, 40(1-2):105-113.
33. Quik M., Huang L.Z., Parameswaran N., Bordia T., Campos C., Perez X.A. Multiple roles for nicotine in Parkinson's disease. Biochem. Pharmacol. 2009, 78:677-685.
34. Schochet T.L., Kelley A.E., Landry C.F. Differential behavioral effects of nicotine exposure in adolescent and adult rats. Psychopharmacology (Berl.) 2004, 175:265-273.
35. Schotte A., Janssen P.F., Megens A.A., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993, 631:191-202.
36. Scorza M.C., Meikle M.N., Hill X.L., Richeri A., Lorenzo D., Artigas F. Prefrontal cortex lesions cause only minor effects on the hyperlocomotion induced by MK-801 and its reversal by clozapine. Int. J. Neuropsychopharmacol. 2008, 11:519-532.
37. Stolerman I.P., Bunker P., Jarvik M.E. Nicotine tolerance in rats; role of dose and dose interval. Psychopharmacologia 1974, 34:317-324.
38. Tutka P. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opin. Investig. Drugs 2008, 17:1473-1485.
39. Tutka P., Zatonski W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. Pharmacol. Rep. 2006, 58:777-798.
40. Vezina P., McGehee D.S., Green W.N. Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1625-1638.
41. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997, 20:92-98.